Janux Therapeutics, Inc. Deferred Income Tax Expense (Benefit)
Janux Therapeutics, Inc. (JANX) reported Deferred Income Tax Expense (Benefit) of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2025-02-27
- Janux Therapeutics, Inc. deferred income tax expense (benefit) for fiscal 2024 was $0.00.
- Janux Therapeutics, Inc. deferred income tax expense (benefit) for fiscal 2023 was $0.00.
- Janux Therapeutics, Inc. deferred income tax expense (benefit) for fiscal 2022 was $0.00.
- Janux Therapeutics, Inc. deferred income tax expense (benefit) for fiscal 2021 was $0.00.
| Period end | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-27 |
| 2023-12-31 | $0.00 10-K · filed 2025-02-27 |
| 2022-12-31 | $0.00 10-K · filed 2025-02-27 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-10 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |